Analysts predict that RXi Pharmaceuticals Corporation (NASDAQ:RXII) will post ($0.11) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for RXi Pharmaceuticals Corporation’s earnings. RXi Pharmaceuticals Corporation posted earnings per share of ($0.34) in the same quarter last year, which would indicate a positive year over year growth rate of 67.6%. The company is scheduled to issue its next quarterly earnings results on Thursday, November 9th.

According to Zacks, analysts expect that RXi Pharmaceuticals Corporation will report full-year earnings of ($0.74) per share for the current financial year. For the next fiscal year, analysts forecast that the business will report earnings of ($0.57) per share. Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover RXi Pharmaceuticals Corporation.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). During the same period in the prior year, the firm earned ($0.34) EPS.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate RXi Pharmaceuticals Corporation (RXII) Will Announce Earnings of -$0.11 Per Share” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at

RXi Pharmaceuticals Corporation (NASDAQ:RXII) traded down 1.75% during trading on Monday, hitting $0.56. The company’s stock had a trading volume of 72,462 shares. RXi Pharmaceuticals Corporation has a 12 month low of $0.51 and a 12 month high of $2.93. The firm has a 50 day moving average of $0.60 and a 200 day moving average of $0.65. The firm’s market cap is $13.02 million.

A hedge fund recently raised its stake in RXi Pharmaceuticals Corporation stock. Renaissance Technologies LLC increased its position in RXi Pharmaceuticals Corporation (NASDAQ:RXII) by 26.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 229,980 shares of the biotechnology company’s stock after purchasing an additional 48,200 shares during the period. Renaissance Technologies LLC owned 3.49% of RXi Pharmaceuticals Corporation worth $164,000 at the end of the most recent reporting period. Institutional investors own 1.70% of the company’s stock.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Get a free copy of the Zacks research report on RXi Pharmaceuticals Corporation (RXII)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related stocks with our FREE daily email newsletter.